<html><head></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><div><br></div><span id="OLK_SRC_BODY_SECTION"><div class="gmail_extra"><div class="gmail_quote"><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex"><div><br></div></blockquote></div></div><div>Dear Jeffrey</div><div><br></div><div><span class="Apple-tab-span" style="white-space: pre; "> </span>I am looking for some evidence about the use of the lipid formulations oaf Ampho B (ABELCET and AMBISOME) for the therapy of refractory or intolerant mucocutaneous leishmaniasis? </div><div><span class="Apple-tab-span" style="white-space: pre; "> </span>Is there any published controlled clinical trial? Do you have any personal experience using AMBISOME or ABELCET on Mucocutaneous Leishmaniasis? </div><div><span class="Apple-tab-span" style="white-space: pre; "> </span>Bets Regards</div><div><span class="Apple-tab-span" style="white-space: pre; "> </span>Flavio Queiroz-Telles M</div><div><span class="Apple-tab-span" style="white-space: pre; "> </span>Federal University of Parana, Brazil</div></span></body></html>